Daratumumab, lenalidomide, and dexamethasone in systemic light‐chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21
Gespeichert in:
| Veröffentlicht in: | American journal of hematology 2021-07, Vol.96 (7), p.E253-E257 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | E257 |
|---|---|
| container_issue | 7 |
| container_start_page | E253 |
| container_title | American journal of hematology |
| container_volume | 96 |
| creator | Kimmich, Christoph R. Terzer, Tobias Benner, Axel Hansen, Timon Carpinteiro, Alexander Dittrich, Tobias Veelken, Kaya Jauch, Anna Huhn, Stefanie Basset, Marco Goldschmidt, Hartmut Müller‐Tidow, Carsten Schönland, Stefan O. Hegenbart, Ute |
| description | |
| doi_str_mv | 10.1002/ajh.26191 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2512313740</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2538352137</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3881-edde41be621090cf2d6347a495a740bf0832a7be873cc1c2478f1e913536535b3</originalsourceid><addsrcrecordid>eNp1kc1u1DAQxy1ERZfCgRdAlriAtNv6K4nDrSofW1SJC5wjx550vbLj1nZKc-MRuPJ6PAne3cIBidOMxr_5SeM_Qi8oOaWEsDO13Zyymrb0EVpQ0tYrWVfsMVoQXtPSk_YYPU1pSwilQpIn6JhzKYSsxQL9fKeiypOfvOqX2MGonDXBWwNLrEaDDdwrD3mjUhgB2xGnOWXwVmNnrzf51_cfeqPKWPnZhbKZbHqL1-UJwzBYrfS8xBEc3Kkx4xzurbZ53pv9fs3cQUywg0FnHAZ8vRvTW0afoaNBuQTPH-oJ-vrh_ZeL9erq88fLi_OrleZS0hUYA4L2ULNyOdEDMzUXjRJtpRpB-oFIzlTTg2y41lQz0ciBQkt5xeuKVz0_Qa8P3psYbidIufM2aXBOjRCm1LGKMk55kRX01T_oNkyxfNmO4pJXrHCFenOgdAwpRRi6m2i9inNHSbfLqyt5dfu8CvvywTj1Hsxf8k9ABTg7AN-sg_n_pu780_qg_A0ur6B3</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2538352137</pqid></control><display><type>article</type><title>Daratumumab, lenalidomide, and dexamethasone in systemic light‐chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21</title><source>Wiley Free Content</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Kimmich, Christoph R. ; Terzer, Tobias ; Benner, Axel ; Hansen, Timon ; Carpinteiro, Alexander ; Dittrich, Tobias ; Veelken, Kaya ; Jauch, Anna ; Huhn, Stefanie ; Basset, Marco ; Goldschmidt, Hartmut ; Müller‐Tidow, Carsten ; Schönland, Stefan O. ; Hegenbart, Ute</creator><creatorcontrib>Kimmich, Christoph R. ; Terzer, Tobias ; Benner, Axel ; Hansen, Timon ; Carpinteiro, Alexander ; Dittrich, Tobias ; Veelken, Kaya ; Jauch, Anna ; Huhn, Stefanie ; Basset, Marco ; Goldschmidt, Hartmut ; Müller‐Tidow, Carsten ; Schönland, Stefan O. ; Hegenbart, Ute</creatorcontrib><identifier>ISSN: 0361-8609</identifier><identifier>EISSN: 1096-8652</identifier><identifier>DOI: 10.1002/ajh.26191</identifier><identifier>PMID: 33844864</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Amyloidosis ; Dexamethasone ; Hematology ; Immunotherapy ; Monoclonal antibodies ; Steroids ; Targeted cancer therapy ; Toxicity</subject><ispartof>American journal of hematology, 2021-07, Vol.96 (7), p.E253-E257</ispartof><rights>2021 The Authors. published by Wiley Periodicals LLC.</rights><rights>2021. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3881-edde41be621090cf2d6347a495a740bf0832a7be873cc1c2478f1e913536535b3</citedby><cites>FETCH-LOGICAL-c3881-edde41be621090cf2d6347a495a740bf0832a7be873cc1c2478f1e913536535b3</cites><orcidid>0000-0003-1917-6746 ; 0000-0003-3829-0499</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fajh.26191$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fajh.26191$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33844864$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kimmich, Christoph R.</creatorcontrib><creatorcontrib>Terzer, Tobias</creatorcontrib><creatorcontrib>Benner, Axel</creatorcontrib><creatorcontrib>Hansen, Timon</creatorcontrib><creatorcontrib>Carpinteiro, Alexander</creatorcontrib><creatorcontrib>Dittrich, Tobias</creatorcontrib><creatorcontrib>Veelken, Kaya</creatorcontrib><creatorcontrib>Jauch, Anna</creatorcontrib><creatorcontrib>Huhn, Stefanie</creatorcontrib><creatorcontrib>Basset, Marco</creatorcontrib><creatorcontrib>Goldschmidt, Hartmut</creatorcontrib><creatorcontrib>Müller‐Tidow, Carsten</creatorcontrib><creatorcontrib>Schönland, Stefan O.</creatorcontrib><creatorcontrib>Hegenbart, Ute</creatorcontrib><title>Daratumumab, lenalidomide, and dexamethasone in systemic light‐chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21</title><title>American journal of hematology</title><addtitle>Am J Hematol</addtitle><subject>Amyloidosis</subject><subject>Dexamethasone</subject><subject>Hematology</subject><subject>Immunotherapy</subject><subject>Monoclonal antibodies</subject><subject>Steroids</subject><subject>Targeted cancer therapy</subject><subject>Toxicity</subject><issn>0361-8609</issn><issn>1096-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNp1kc1u1DAQxy1ERZfCgRdAlriAtNv6K4nDrSofW1SJC5wjx550vbLj1nZKc-MRuPJ6PAne3cIBidOMxr_5SeM_Qi8oOaWEsDO13Zyymrb0EVpQ0tYrWVfsMVoQXtPSk_YYPU1pSwilQpIn6JhzKYSsxQL9fKeiypOfvOqX2MGonDXBWwNLrEaDDdwrD3mjUhgB2xGnOWXwVmNnrzf51_cfeqPKWPnZhbKZbHqL1-UJwzBYrfS8xBEc3Kkx4xzurbZ53pv9fs3cQUywg0FnHAZ8vRvTW0afoaNBuQTPH-oJ-vrh_ZeL9erq88fLi_OrleZS0hUYA4L2ULNyOdEDMzUXjRJtpRpB-oFIzlTTg2y41lQz0ciBQkt5xeuKVz0_Qa8P3psYbidIufM2aXBOjRCm1LGKMk55kRX01T_oNkyxfNmO4pJXrHCFenOgdAwpRRi6m2i9inNHSbfLqyt5dfu8CvvywTj1Hsxf8k9ABTg7AN-sg_n_pu780_qg_A0ur6B3</recordid><startdate>20210701</startdate><enddate>20210701</enddate><creator>Kimmich, Christoph R.</creator><creator>Terzer, Tobias</creator><creator>Benner, Axel</creator><creator>Hansen, Timon</creator><creator>Carpinteiro, Alexander</creator><creator>Dittrich, Tobias</creator><creator>Veelken, Kaya</creator><creator>Jauch, Anna</creator><creator>Huhn, Stefanie</creator><creator>Basset, Marco</creator><creator>Goldschmidt, Hartmut</creator><creator>Müller‐Tidow, Carsten</creator><creator>Schönland, Stefan O.</creator><creator>Hegenbart, Ute</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1917-6746</orcidid><orcidid>https://orcid.org/0000-0003-3829-0499</orcidid></search><sort><creationdate>20210701</creationdate><title>Daratumumab, lenalidomide, and dexamethasone in systemic light‐chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21</title><author>Kimmich, Christoph R. ; Terzer, Tobias ; Benner, Axel ; Hansen, Timon ; Carpinteiro, Alexander ; Dittrich, Tobias ; Veelken, Kaya ; Jauch, Anna ; Huhn, Stefanie ; Basset, Marco ; Goldschmidt, Hartmut ; Müller‐Tidow, Carsten ; Schönland, Stefan O. ; Hegenbart, Ute</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3881-edde41be621090cf2d6347a495a740bf0832a7be873cc1c2478f1e913536535b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Amyloidosis</topic><topic>Dexamethasone</topic><topic>Hematology</topic><topic>Immunotherapy</topic><topic>Monoclonal antibodies</topic><topic>Steroids</topic><topic>Targeted cancer therapy</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kimmich, Christoph R.</creatorcontrib><creatorcontrib>Terzer, Tobias</creatorcontrib><creatorcontrib>Benner, Axel</creatorcontrib><creatorcontrib>Hansen, Timon</creatorcontrib><creatorcontrib>Carpinteiro, Alexander</creatorcontrib><creatorcontrib>Dittrich, Tobias</creatorcontrib><creatorcontrib>Veelken, Kaya</creatorcontrib><creatorcontrib>Jauch, Anna</creatorcontrib><creatorcontrib>Huhn, Stefanie</creatorcontrib><creatorcontrib>Basset, Marco</creatorcontrib><creatorcontrib>Goldschmidt, Hartmut</creatorcontrib><creatorcontrib>Müller‐Tidow, Carsten</creatorcontrib><creatorcontrib>Schönland, Stefan O.</creatorcontrib><creatorcontrib>Hegenbart, Ute</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kimmich, Christoph R.</au><au>Terzer, Tobias</au><au>Benner, Axel</au><au>Hansen, Timon</au><au>Carpinteiro, Alexander</au><au>Dittrich, Tobias</au><au>Veelken, Kaya</au><au>Jauch, Anna</au><au>Huhn, Stefanie</au><au>Basset, Marco</au><au>Goldschmidt, Hartmut</au><au>Müller‐Tidow, Carsten</au><au>Schönland, Stefan O.</au><au>Hegenbart, Ute</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Daratumumab, lenalidomide, and dexamethasone in systemic light‐chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21</atitle><jtitle>American journal of hematology</jtitle><addtitle>Am J Hematol</addtitle><date>2021-07-01</date><risdate>2021</risdate><volume>96</volume><issue>7</issue><spage>E253</spage><epage>E257</epage><pages>E253-E257</pages><issn>0361-8609</issn><eissn>1096-8652</eissn><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>33844864</pmid><doi>10.1002/ajh.26191</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0003-1917-6746</orcidid><orcidid>https://orcid.org/0000-0003-3829-0499</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0361-8609 |
| ispartof | American journal of hematology, 2021-07, Vol.96 (7), p.E253-E257 |
| issn | 0361-8609 1096-8652 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2512313740 |
| source | Wiley Free Content; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Amyloidosis Dexamethasone Hematology Immunotherapy Monoclonal antibodies Steroids Targeted cancer therapy Toxicity |
| title | Daratumumab, lenalidomide, and dexamethasone in systemic light‐chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T23%3A48%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Daratumumab,%20lenalidomide,%20and%20dexamethasone%20in%20systemic%20light%E2%80%90chain%20amyloidosis:%20High%20efficacy,%20relevant%20toxicity%20and%20main%20adverse%20effect%20of%20gain%201q21&rft.jtitle=American%20journal%20of%20hematology&rft.au=Kimmich,%20Christoph%20R.&rft.date=2021-07-01&rft.volume=96&rft.issue=7&rft.spage=E253&rft.epage=E257&rft.pages=E253-E257&rft.issn=0361-8609&rft.eissn=1096-8652&rft_id=info:doi/10.1002/ajh.26191&rft_dat=%3Cproquest_cross%3E2538352137%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2538352137&rft_id=info:pmid/33844864&rfr_iscdi=true |